TABLE 1.

Characteristics of participants randomly assigned to standard or sequential therapy and among those with post-treatment status for per-protocol analysis

	Standard therapy (PPI-CA) group		Sequential therapy group
	Randomized* (n=53)	Per-protocol† (n=49)	Randomized* (n=51)	Per-protocol† (n=40)
Age, years, mean (95% CI)	42 (38–47)	43 (38–48)	38 (34–43)	38 (33–43)
Male sex	49 (35–63)	49 (35–63)	49 (35–63)	55 (39–71)
Aboriginal ethnicity	91 (82–99)	90 (81–98)	94 (87–100)	92 (84–100)
Nonsmoker‡	38 (25–52)	42 (27–56)	35 (21–49)	42 (26–58)
Any alcohol intake	67 (54–80)	65 (51–78)	58 (44–73)	58 (42–74)
No epigastric symptoms‡	31 (19–46)	30 (17–45)	40 (26–56)	39 (24–57)
No comorbidities	87 (77–96)	88 (78–97)	77 (65–89)	76 (62–90)
On PPI treatment‡	6 (1–17)	6 (1–17)	2 (0–11)	0 (–)

Data presented as % (95% CI) unless otherwise indicated.

^*Includes participants lost to follow-up;

^†Restricted to participants with post-treatment urea breath test result;

^‡Missing data: One in the proton pump inhibitor (PPI)-clarithromycin amoxicillin (PPI-CA) group, two in the standard therapy group